03-Nov-2026 21:20:40
AARTIDRUGSGeneral news
AARTIDRUGS Q2 : CONS NET PROFIT UP 83% AT 82.8 CR (YOY), UP 65% (QOQ). STRONG (On 1st Look)
Revenue up 27% at 828.8 Cr (YOY), up 18% (QOQ). Ebitda up 63% at 137.9 Cr (YOY); margins 16.6% v 12.9% (YOY), 13.8% (QOQ). Formulation revenue up 58% at 130.0 Cr (YOY); Specialty Chemicals up 92% at 71.8 Cr (YOY). API segment revenue up 17% at 604.5 Cr (YOY), up 18% (QOQ). Caution: none stated; margins highest in nearly six years per management.
Aarti Drugs Ltd
Open attachment